Dare Bioscience, Inc. Income Statement
DARE|7 years of annual SEC 10-K data (FY2014-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Dare Bioscience, Inc. reported $9,784 in revenue and $4M in net loss for FY2025. Revenue has declined at a 31.5% compound annual rate over the past 11 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|
| Revenue | $9.8K | $2.8M | $10.0M | $0 | $80.0K | $6.0K | $625.0K |
| Cost of Revenue | $0 | - | - | - | - | - | - |
| SG&A Expense | $9.2M | $12.1M | $11.2M | $8.4M | $8.6M | $6.2M | $6.4M |
| R&D Expense | $14.3M | $21.5M | $30.0M | $30.6M | $11.8M | $9.7M | $15.8M |
| Operating Income | -$23.5M | -$30.9M | -$31.4M | -$39.1M | - | - | - |
| Interest Expense | - | - | - | - | $1.1M | $1.5M | $567.0K |
| Income Tax | $0 | $0 | $0 | $0 | - | - | - |
| Net Income | -$4.1M | -$30.2M | -$30.9M | -$38.7M | -$23.3M | -$17.1M | -$22.1M |
| EPS (Basic) | -$0.48 | -$4.15 | -$0.37 | -$0.63 | - | - | - |
| EPS (Diluted) | -$0.48 | -$4.15 | -$0.37 | -$0.63 | -$1.60 | -$25.05 | -$36.39 |
| Shares Outstanding | 8.7M | 8.3M | 84.8M | 83.9M | 27.3M | 20.1M | 785.5K |
| Operating Margin | -239692.2% | -1101.9% | -313.9% | - | - | - | - |
| Profit Margin | -41430.9% | -1074.2% | -309.5% | - | -29177.5% | -285716.7% | -3536.2% |